[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Iuliu Hatieganu University of Medicine and Pharmacy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":210},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,37,62,89,118,149,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":34,"locationsCount":4},"100644737","parents-knowledge-and-attitudes-towards-vaccinating-their-children-100644737",false,"NCT07672886","Parents' Knowledge and Attitudes Towards Vaccinating Their Children","Inclusion Criteria:\n\n\\- parents of patients under 18 years of age admitted to the Emergency Children's Hospital, Cluj-Napoca, Paediatrics Clinic III during January -sept 2026\n\nExclusion Criteria:\n\n\\- parent of patients under 18 years who refuse to participate or to fill in the questionnaire and the consent form","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","Purpose: To identify and evaluate the factors that influence parents' attitudes towards vaccination.\n\nObjectives:\n\n1. To assess parents' level of knowledge about vaccines\n2. To assess parents' attitudes and behavior regarding vaccine administration.\n3. To observe whether there is a link between various socio-demographic factors and their knowledge about vaccines.\n4. To assess the relationship and communication between doctors and parents.\n5. To evaluate the influence of the COVID-19 pandemic on parents' trust in vaccines.\n\nMethod Distribution of questionnaires to parents of patients under 18 years of age admitted in the Emergency Children's Hospital, Cluj-Napoca, Paediatrics Clinic III. Collection of clinical data by applying questionnaires completed voluntarily by parents",[25],"Vaccine Hesitancy","NOT_YET_RECRUITING","2026-06-22",{"date":29,"type":30},"2026-06-29","ACTUAL",{"date":32,"type":19},"2026-07-01",{"date":32,"type":19},{"name":35,"class":36},"Iuliu Hatieganu University of Medicine and Pharmacy","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":43,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":46,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100641258","the-impact-of-anaesthesia-on-inflammation-and-netosis-in-hepatocellular-carcinoma-resection-100641258","NCT07657897","The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection","Inclusion Criteria:\n\n* patients with a hepatocellular carcinoma suitable for RFA\n* tumor measuring up to 3 cm in diameter\n* ASA I, II, or III\n\nExclusion Criteria:\n\n* candidates for surgery\n* chronic immunosuppressive medication\n* contraindications to any of the study medications\n* patients with psychiatric disorders\n* autoimmune disorders\n* corticosteroid-dependent bronchial asthma\n* congenital or acquired coagulation disorders\n* HIV-positive patients\n* pregnant women\n* antiarrhythmic therapy","80 Years",{"count":45,"type":19},100,[22],"According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC). The latter currently ranks 16th among the leading causes of death worldwide.\n\nCurrent research focuses on investigating novel therapeutic modalities, optimizing surgical and anesthetic practices, and identifying biological biomarkers to predict disease progression and severity. In this study, we address radiofrequency ablation (RFA) with the goal of improving periprocedural prognosis, recurrence rates, and overall survival. Specifically, we will quantify the expression of NETosis, a relatively novel biomarker with potential therapeutic and prognostic value in HCC progression. NETosis is a regulated form of cell death through which granulocytes release decondensed chromatin and various proteases into the extracellular space, forming a web-like meshwork known as neutrophil extracellular traps (NETs). These structures are actively involved in hepatic tumorigenesis by promoting tumor growth and metastasis.\n\nRecent clinical data reveal that NETs play a key role in:\n\nLocal tumor progression\n\nThe incidence of hepatic metastasis\n\nDirect modulation of the immune response\n\nHepatic ischemia-reperfusion injury\n\nSeveral recent studies demonstrate that the in vivo blockade of NETosis reduces tumor recurrence, mitigates the pro-inflammatory state, and serves as a valuable prognostic indicator in advanced liver disease \\[2,3,4\\]. To suppress NETosis expression and ultimately lower recurrence rates, our protocol evaluates the intraprocedural administration of 1% lidocaine followed by a continuous postoperative intravenous lidocaine infusion.",[49,50,51],"Hepato Cellular Carcinoma (HCC)","Sedation and Analgesia","Ablation Techniques","RECRUITING","2026-06-13",{"date":55,"type":30},"2026-06-18",{"date":57,"type":30},"2024-11-12",{"date":59,"type":19},"2026-11-12",{"name":35,"class":36},1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":5},"100623473","using-routine-inflammatory-and-metabolic-blood-tests-bedside-included-to-predict-brain-injury-in-children-after-minor-head-trauma-100623473","NCT07397091","Using Routine Inflammatory and Metabolic Blood Tests (Bedside Included) to Predict Brain Injury in Children After Minor Head Trauma","ROUTINE INFLAMMATORY AND METABOLIC BIOMARKERS. Can They Predict a Positive Head CT in Paediatric Minor Traumatic Brain Injury?","paeds_mTBI_Bio","Inclusion Criteria:\n\nPatients aged 0 to 18 years old presenting to the ED with mild traumatic brain injury (with or without cervical injury):\n\n1. Mild TBI will be defined as GCS 14-15 or A (AVPU) upon admission\n2. Patients underwent head CT\n3. Routine blood biomarkers have been collected (complete blood count - CBC, biochemistry and\u002For (arterial) venos blood gases - (A)VBG).\n\nExclusion Criteria:\n\n* Patients with moderate (GCS 13-9 or V) or severe (GCS 8-3 or P,U) head trauma\n* Patients with associated trauma (limb\u002Frib\u002Fpelvic fractures, organ injuries).",{"count":71,"type":19},800,"OBSERVATIONAL","Traumatic brain injury (TBI) poses significant strains on the paediatric population, for which the possible side effects of diagnostic imagistics could induce life-altering conditions. Routine inflammatory and metabolic biomarkers (complete blood count, C reactive protein, glucose) are frequently sampled in the paediatric patients admited within emergency departments, including the low-resource settings. This study aims to retrospectively document whether such routine blood biomarkers could predict a positive head CT scan and subsequently contribute to a prediction score, ment to enable more accurate decision on which minor TBI paediatric patients should be submitted to diagnotic imagistics.",[75],"Brain Injury Traumatic Mild",[77,78,79,80],"routine biomarkers","traumatic brain injury","inflammatory","metabolic","2026-03-25",{"date":83,"type":30},"2026-03-31",{"date":85,"type":19},"2026-04-20",{"date":87,"type":19},"2026-06-20",{"name":35,"class":36},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":43,"enrollmentInfo":96,"targetDuration":4,"studyType":20,"phases":98,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":61},"100625516","phase-4-continous-infusion-of-nefopam-for-patients-undergoing-pancreatoduodenectomy-100625516","NCT07423650","Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy","Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy: A Randomized Controlled Double-Blind Trial","Inclusion Criteria:\n\n1. Patients scheduled for elective pancreatoduodenectomy surgery\n2. Agreed to participate in the study\n\nExclusion Criteria:\n\n1. Refusal to participate\n2. Emergency surgery\n3. Patients with neurological disorders or other muscular or psychiatric disorders that impede communication\n4. Known allergic reactions to the used medication\n5. Known hyperalgesia\n6. Chronic opioid consumption\n7. Patients that require reintervention in the first 48h postoperatively\n8. Patients with pancreaticogastrostomy",{"count":97,"type":19},93,[99],"PHASE4","The goal of this clinical trial is to determine whether continuous nefopam administration, as part of a multimodal analgesia strategy, reduces opioid consumption and improves patient satisfaction after pancreatoduodenectomy.\n\nThe main questions are:\n\nDoes nefopam administration reduce opioid consumption after pancreatoduodenectomy?\n\nDoes nefopam administration reduce postoperative pain levels after pancreatoduodenectomy?\n\nResearchers will compare two other analgesic strategies, namely continuous lidocaine infusion and epidural analgesia, to assess whether they lead to better outcomes.\n\nParticipants will complete the QoR-15 questionnaire and report their pain levels at predefined time points before and after surgery.",[102,103,104,105],"Pancreatoduodenectomy","Pain Management","Opioid Analgesia","Multimodal Analgesia",[107,102,108,109],"Nefopam","Opioids","Multimodal analgesia","2026-03-19",{"date":112,"type":30},"2026-03-24",{"date":114,"type":19},"2026-03",{"date":116,"type":19},"2026-10",{"name":35,"class":36},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":20,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":61},"100629486","synbiotic-supplement-with-botanical-extracts-for-gut-microbiota-balance-in-irritable-bowel-syndrome-100629486","NCT07475299","Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome","The Impact of a Synbiotic Supplement Containing Botanical Extracts and Multiple Probiotic Strains on Gut Microbiota Balance in Patients With Irritable Bowel Syndrome: A Pilot Prospective Interventional Study","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Clinically confirmed diagnosis of Irritable Bowel Syndrome documented in the medical record\n* Presence of recurrent gastrointestinal symptoms such as bloating, abdominal discomfort, gas, or bowel habit disturbances (constipation, diarrhea, or mixed pattern) considered clinically relevant by the participant\n* Ability to understand the study procedures and provide written informed consent\n* Willingness to participate for the full duration of the study (approximately 16 weeks) and attend study visits (T0, T1, and Tfinal)\n* Willingness to provide biological samples (blood and stool samples for microbiota analysis) according to the study protocol\n\nExclusion Criteria:\n\n* Known or suspected organic gastrointestinal disease explaining the symptoms (e.g., inflammatory bowel disease, untreated celiac disease, gastrointestinal malignancy)\n* Presence of alarm symptoms such as unexplained gastrointestinal bleeding, significant unintentional weight loss, persistent fever, severe anemia, or signs of acute infection\n* Acute gastrointestinal infection at the time of screening\n* Use of antibiotics within the previous 4-8 weeks prior to baseline\n* Use of probiotic, prebiotic, or microbiota-modifying supplements within 4 weeks prior to baseline that cannot be discontinued\n* Planned major dietary changes or initiation of new treatments for gastrointestinal symptoms during the study period\n* Pregnancy or breastfeeding\n* Known allergy or hypersensitivity to any component of the investigational supplement\n* Any severe comorbid condition or circumstance that, in the opinion of the investigator, could increase risk to the participant or interfere with study results","70 Years",{"count":127,"type":19},8,[22],"The goal of this clinical trial is to evaluate whether a synbiotic dietary supplement containing botanical extracts and multiple probiotic strains can improve gastrointestinal symptoms and modulate gut microbiota composition in adults diagnosed with Irritable Bowel Syndrome (IBS).\n\nThe main questions it aims to answer are:\n\nDoes supplementation with the synbiotic product improve functional gastrointestinal symptoms associated with IBS (e.g., bloating, abdominal discomfort, and bowel habit disturbances)?\n\nDoes the intervention lead to measurable changes in gut microbiota composition and selected biological markers compared with baseline measurements?\n\nParticipants will:\n\nundergo baseline evaluation including symptom assessment, blood tests, and stool sample collection for gut microbiota analysis;\n\ncomplete an 8-week observation period without intervention to establish baseline variability;\n\ntake the synbiotic supplement once daily for 8 weeks;\n\nrepeat clinical assessments, blood tests, and gut microbiota analysis during follow-up visits.",[131],"Irritable Bowel Syndrome (IBS)",[133,134,135,136,137,138,139,140],"IBS","Synbiotic","Botanical Extracts","Probiotics","Gastrointestinal Symptoms","Digestive Health","Microbiota Diversity","Irritable Bowel Syndrome","2026-03-14",{"date":143,"type":30},"2026-03-16",{"date":145,"type":19},"2026-04",{"date":147,"type":19},"2027-01",{"name":35,"class":36},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":20,"phases":158,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":61},"100575416","attitudes-towards-deprescribing-medications-in-cancer-patients-and-impact-of-educational-intervention-by-a-clinical-pharmacist-100575416","NCT06771999","Attitudes Towards Deprescribing Medications in Cancer Patients and Impact of Educational Intervention by a Clinical Pharmacist","Attitudes Towards Deprescribing of Non-oncologic Medication in Cancer Pacient and the Impact of an Educational Intervention by a Clinical Pharmacist","Inclusion Criteria:\n\n* cancer patients in palliative treatment\n* ECOG 1-2\n\nExclusion Criteria:\n\n* cancer patients in curative treatment\n* ECOG 3-4\n* cognitive impairment",{"count":157,"type":19},120,[22],"Participation in this study consists in responding to some questions from two questionnaires in Romanian about how participants feel about deprescribing, participants' treatment and how participants understand medical information. After that, participants will receive a brochure and watch a video with some basic information about medications and participants' involvement in treatment decisions and in the next visit for cancer treatment participants will be asked to answer questions from one of the initial questionnaire.",[161,162],"Palliative Care","Cancer",[164,165,166,167,168],"palliative care","cancer","clinical pharmacist","educational intervention","rPATD","2026-02-11",{"date":171,"type":30},"2026-02-13",{"date":173,"type":30},"2025-01-13",{"date":175,"type":19},"2027-04-30",{"name":35,"class":36},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":61},"100535441","electrocoagulation-vs-cold-knife-cutting-in-joint-arthroplasty-electrocoagulation-vs-scalpel-100535441","NCT06251869","Electrocoagulation vs. Cold Knife Cutting in Joint Arthroplasty (Electrocoagulation vs Scalpel)","Electrocoagulation vs. Cold Knife Cutting in Joint Arthroplasty: A Comparative Analysis in Knee and Hip Replacement","evs","Inclusion Criteria:\n\n* Patients who have given informed consent to the procedure\n* Patients admitted over 18 years of age\n* Patients with pathology requiring primary joint replacement (symptomatic gonarthrosis\u002Fcoxarthrosis, Avascular necrosis (AVN) of the femoral head , femoral neck fractures, etc)\n\nExclusion Criteria:\n\n* Contraindications for major surgery or anaesthesia\n* Patients with active infections that could interfere with outcome assessment\n* Patients unable to give informed consent for psychological or cognitive reasons\n* Severe medical conditions such as coagulopathies that may significantly influence outcomes\n* Patients unable or unwilling to adhere to the required follow-up period\n* Patients who died during the study period\n* Patients with revision prosthesis operations","90 Years",{"count":187,"type":19},700,"Comparison of clinical outcomes of electrocoagulation and non-electrocoagulation techniques in total hip and knee arthroplasty surgery",[190],"Compassion",[192,193,194,195,196,197,198,199,200,201],"electrocoagulation","cold knife","scalpel","joint arthroplasty","knee replacement","hip replacement","comparative analysis","surgical techniques","orthopedics","outcome assessment","2025-04-28",{"date":204,"type":30},"2025-05-01",{"date":206,"type":30},"2024-03-15",{"date":208,"type":19},"2027-02-15",{"name":35,"class":36},""]